Objective:To detect the CD90+ cells’ stem cell characteristics in human hepatocellular carcinoma and BEL-7404 cell lines and killed CD90+ liver cancer stem cells(LCSCs) by an anti-CD90 monoclonal antibody targeted thermosensitive magnetoliposomes encapsulated HSP90 inhibition 17-AAG(CD90@17-AAG/TMs). Methods:Immunohistochemical staining was performed to explore the relationship between the expression of CD90 and the clinicopathological parameters of human hepatocellular carcinoma. Magnetic activated cell sorting was performed to isolate the CD90+ cells from the BEL-7404 cell lines and its stem cell characteristics were identified. CD90@17-AAG/TMs was prepared by rotary evaporator-hydration method to kill the CD90+ LCSCs in vivo. Results:There was no significant correlation among the age,sex,tumor size,and AFP with the expression of CD90 in hepatocellular carcinoma tissues(P > 0.05). The expression of CD90 was relative to the pathology classification (P < 0.05). The CD90+ LCSCs showed a significantly stem cell characteristics. CD90@17-AAG/TMs effectively killed CD90+ LCSCs and inhibited the tumor growth. Conclusion:CD90+ LCSCs has significant stem cell characteristics. CD90@17-AAG/TMs can effectively kill CD90+ LCSCs in vivo and inhibit the formation and growth of tumors,which may provide a novel therapy approach for hepatocellular carcinoma and other cancers.